Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.33 |
| ▸ | CCR5 | P51681 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870537 | 0.89 | CHRM2 (0.32) | PLA2G2ACHRM2CCR5MAPTHSD17B10 | |
| SCHEMBL4870423 | 0.89 | NAMPT (0.34) | PLA2G2ACHRM2CCR5RAB9ALMNA | |
| SCHEMBL4872635 | 0.89 | CHRM2 (0.39) | CHRM2CCR5RAB9ALMNAMAPT | |
| SCHEMBL4872589 | 0.89 | CHRM5 (0.34) | CHRM2CCR5LMNAMAPTHSD17B10 | |
| SCHEMBL4873198 | 0.89 | BMP1 (0.38) | CHRM2CCR5RAB9ANPC1LMNA | |
| SCHEMBL4875555 | 0.88 | CHRM2 (0.33) | PLA2G2ACHRM2CCR5RAB9ALMNA | |
| SCHEMBL4872624 | 0.88 | LMNA (0.38) | CHRM2CCR5RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4872570 | 0.87 | CHRM2 (0.34) | CHRM2CCR5MAPTHSD17B10NAMPT | |
| SCHEMBL4870472 | 0.87 | KDM4E (0.39) | CHRM2LMNAMAPTNAMPTSMN1; SMN2 | |
| SCHEMBL4872564 | 0.86 | BMP1 (0.39) | CHRM2LMNAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| EP-1289965-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| WO-2001090081-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | SCD5 914/4885PLA2G2A 2510/4885CHRM2 2/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | SCD5 1176/4885PLA2G2A 2156/4885CHRM2 2/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | SCD5 1176/4885PLA2G2A 2156/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.